Home › Trial NCT07138885
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
- Trial IDNCT07138885
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorSun Yat-sen University
- Enrollment62
- Start date2025-08-01
- ConditionsHepatocellular Carcinoma (HCC) · Second Line Treatment
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.